An anonymous director reports

CLEARMIND MEDICINE ANNOUNCES IT IS IN COMPLIANCE WITH ALL APPLICABLE NASDAQ LISTING STANDARDS

On Dec. 12, 2023, Clearmind Medicine Inc. received a formal notification from the Nasdaq Stock Market LLC that the company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires the company's common shares to maintain a minimum bid price of $1 per share.

The Nasdaq staff made this determination of compliance after the closing bid price of the company's common shares was at $1 per share or greater for the prior 10 consecutive business days. Accordingly, the company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed.

As a result, the scheduled hearing before the Nasdaq Listing Qualifications Hearings Panel requested by the company to stay the suspension of the company's securities from Nasdaq was cancelled. The company is now in compliance with all applicable listing standards and its common shares will continue to be listed and traded on Nasdaq.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The company's intellectual portfolio currently consists of 14 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

We seek Safe Harbor.